Logo image of VERV

VERVE THERAPEUTICS INC (VERV) Stock Fundamental Analysis

NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD

7.3041  -0.53 (-6.72%)

Fundamental Rating

3

Taking everything into account, VERV scores 3 out of 10 in our fundamental rating. VERV was compared to 571 industry peers in the Biotechnology industry. VERV has a great financial health rating, but its profitability evaluates not so good. VERV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERV had negative earnings in the past year.
VERV had a negative operating cash flow in the past year.
VERV had negative earnings in each of the past 5 years.
VERV had a negative operating cash flow in each of the past 5 years.
VERV Yearly Net Income VS EBIT VS OCF VS FCFVERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

VERV has a better Return On Assets (-29.68%) than 68.56% of its industry peers.
With a decent Return On Equity value of -38.74%, VERV is doing good in the industry, outperforming 72.47% of the companies in the same industry.
Industry RankSector Rank
ROA -29.68%
ROE -38.74%
ROIC N/A
ROA(3y)-27.03%
ROA(5y)-45.74%
ROE(3y)-31.87%
ROE(5y)-99.45%
ROIC(3y)N/A
ROIC(5y)N/A
VERV Yearly ROA, ROE, ROICVERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

VERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERV Yearly Profit, Operating, Gross MarginsVERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

VERV does not have a ROIC to compare to the WACC, probably because it is not profitable.
VERV has more shares outstanding than it did 1 year ago.
VERV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VERV Yearly Shares OutstandingVERV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M
VERV Yearly Total Debt VS Total AssetsVERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 0.94, we must say that VERV is in the distress zone and has some risk of bankruptcy.
VERV has a better Altman-Z score (0.94) than 66.07% of its industry peers.
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.94
ROIC/WACCN/A
WACC9.56%
VERV Yearly LT Debt VS Equity VS FCFVERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 13.05 indicates that VERV has no problem at all paying its short term obligations.
VERV has a better Current ratio (13.05) than 85.44% of its industry peers.
A Quick Ratio of 13.05 indicates that VERV has no problem at all paying its short term obligations.
The Quick ratio of VERV (13.05) is better than 85.61% of its industry peers.
Industry RankSector Rank
Current Ratio 13.05
Quick Ratio 13.05
VERV Yearly Current Assets VS Current LiabilitesVERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

VERV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.65%, which is quite impressive.
The Revenue has grown by 220.16% in the past year. This is a very strong growth!
EPS 1Y (TTM)20.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.06%
Revenue 1Y (TTM)220.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%120.24%

3.2 Future

The Earnings Per Share is expected to decrease by -0.84% on average over the next years.
Based on estimates for the next years, VERV will show a small growth in Revenue. The Revenue will grow by 5.34% on average per year.
EPS Next Y18.3%
EPS Next 2Y2.46%
EPS Next 3Y1.26%
EPS Next 5Y-0.84%
Revenue Next Year212.54%
Revenue Next 2Y45.79%
Revenue Next 3Y9.45%
Revenue Next 5Y5.34%

3.3 Evolution

VERV Yearly Revenue VS EstimatesVERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
VERV Yearly EPS VS EstimatesVERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERV Price Earnings VS Forward Price EarningsVERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERV Per share dataVERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.46%
EPS Next 3Y1.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERVE THERAPEUTICS INC

NASDAQ:VERV (2/21/2025, 11:22:53 AM)

7.3041

-0.53 (-6.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners91.55%
Inst Owner Change4.03%
Ins Owners1.73%
Ins Owner Change-0.32%
Market Cap618.37M
Analysts84
Price Target23.33 (219.41%)
Short Float %16.54%
Short Ratio8.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.22%
Min EPS beat(2)15.43%
Max EPS beat(2)17.01%
EPS beat(4)4
Avg EPS beat(4)17.26%
Min EPS beat(4)15.43%
Max EPS beat(4)18.87%
EPS beat(8)7
Avg EPS beat(8)13.45%
EPS beat(12)8
Avg EPS beat(12)5.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)156.45%
Min Revenue beat(2)139.53%
Max Revenue beat(2)173.37%
Revenue beat(4)4
Avg Revenue beat(4)205%
Min Revenue beat(4)139.53%
Max Revenue beat(4)331.46%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.68%
PT rev (3m)-8.96%
EPS NQ rev (1m)0.44%
EPS NQ rev (3m)0.85%
EPS NY rev (1m)0.4%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)11.11%
Revenue NQ rev (3m)20.91%
Revenue NY rev (1m)4.55%
Revenue NY rev (3m)11.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.35
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-2.46
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.29
BVpS6.01
TBVpS6.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.68%
ROE -38.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.03%
ROA(5y)-45.74%
ROE(3y)-31.87%
ROE(5y)-99.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69%
Cap/Sales 18.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.05
Quick Ratio 13.05
Altman-Z 0.94
F-Score5
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)308.6%
Cap/Depr(5y)574.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.06%
EPS Next Y18.3%
EPS Next 2Y2.46%
EPS Next 3Y1.26%
EPS Next 5Y-0.84%
Revenue 1Y (TTM)220.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%120.24%
Revenue Next Year212.54%
Revenue Next 2Y45.79%
Revenue Next 3Y9.45%
Revenue Next 5Y5.34%
EBIT growth 1Y-4.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.38%
EBIT Next 3Y-18.49%
EBIT Next 5YN/A
FCF growth 1Y-27.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.09%
OCF growth 3YN/A
OCF growth 5YN/A